Recent Updates
Recently added Catalysts

Japanese Encephalitis Vaccine

Phase 3

Rabies | Monoclonal antibody | Infectious Disease |Novartis AG|Last Updated: Dec 8, 2014

Target and mechanism

ModalityMonoclonal antibody

Also known as Japanese Encephalitis

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment661

FDA Designations

No designations recorded

Clinical trial landscape

Japanese Encephalitis Vaccine · 1 trial · 2 indications

Phase 3 1
NCT01662440Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult SubjectsRabies
COMPLETED661 Analytics
PHASE3COMPLETED
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
RabiesUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination
Day 7 after last active vaccination (day 15 - group that received accelerated schedule, day 36 - group that received conventional schedule)

Immune response was measured as the percentage of subjects with rabies virus neutralizing antibody (RVNA) concentrations ≥0.5 IU/mL, evaluated using the rapid fluorescent focus inhibition test at day 7 after last active vaccination, i.e. the third out of four vaccinations given in the accelerated Rabies vaccine schedule and the fourth out of four vaccinations given in the conventional Rabies vaccine schedule. As per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs R - Conv.

Percentages of Subjects With PRNT50 Titer ≥1:10 At 28 Days After Last Active Vaccination
Day 28 after last active vaccination (day 36 - group that received accelerated schedule, day 57 - group that received conventional schedule)

Immune response was measured as the percentages of subjects with a titer of ≥1:10 in a 50% plaque reduction neutralization test (PRNT50) 28 days after last active vaccination, ie, the second out of three vaccinations given in the accelerated JE vaccine schedule and the third out of three vaccinations given in the conventional JE vaccine schedule. As per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs JE - Conv.

Secondary Endpoints

RVNA Geometric Mean Concentrations (GMCs) At 28 Days After Last Active Vaccination
Day 57 (28 days after last active vaccination)
PRNT50 Geometric Mean Titers (GMTs) At 28 Days After Last Active Vaccination
Day 57 (28 days after last active vaccination)
Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 28 Days After Last Active Vaccination
Day 36 and day 57 (28 days after last active vaccination)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
R/JE - ConvACTIVE_COMPARATORSubjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
R/JE - AccEXPERIMENTALSubjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
R - ConvACTIVE_COMPARATORSubjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
JE - ConvACTIVE_COMPARATORSubjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.

Interventions

NameTypeDescription
RabiesBIOLOGICALSubjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
Japanese EncephalitisBIOLOGICALSubjects received two doses of Japanese Encephalitis vaccine.
PlaceboOTHERSubjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: 1. Males and females between 18 and 65 years of age (inclusive). 2. Subjects who have given written consent. 3. Individuals in good health as per investigator judgement. Exclusion Criteria: 1. If female, pregnancy or unwillingness to practice acceptable contraception. 2. If fe...

Countries:AustriaGermanySwitzerland
Unlock Eligibility Criteria